Correlation of high body mass index with more advanced localized prostate cancer at radical prostatectomy is not reflected in PSA level and PSA density but is seen in PSA mass

American Journal of Clinical Pathology

Volumn 144, Issue 2, 2015, Pages 271-277

  Kryvenko, Oleksandr N ^a,b,c   Epstein, Jonathan I ^b   Meier, Frederick A ^c   Gupta, Nilesh S ^c   Menon, Mani ^c   Diaz, Mireya ^c  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

BMI; Prostate cancer; Prostatectomy; PSA; PSA mass

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ANALYTICAL PARAMETERS; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; BODY MASS; CANCER SURGERY; CONTROLLED STUDY; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE SPECIFIC ANTIGEN DENSITY; PROSTATE SPECIFIC ANTIGEN MASS; PROSTATE WEIGHT; PROSTATECTOMY; TUMOR VOLUME; BLOOD; COMPLICATION; MIDDLE AGED; NOMOGRAM; PATHOLOGY; PROSTATIC NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; HUMANS; MALE; MIDDLE AGED; NOMOGRAMS; OBESITY; OVERWEIGHT; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84942592906     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPQL9MKQ6VDDWL     Document Type: Article

References (37)

1. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA. 1993;270:860-864.
2. Carter HB, Albertsen PC, Barry MJ, et al. Early detection of prostate cancer: AUA guideline. J Urol. 2013;190:419-426.
3. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006;98:1521-1527.
4. Bazinet M, Meshref AW, Trudel C, et al. Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology. 1994;43:44-51.
5. Miele ME. Percent free PSA as an additional measure in a prostate cancer screen. Clin Lab Sci. 2001;14:102-107.
6. Uzzo RG, Pinover WH, Horwitz EM, et al. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digital rectal examination. Urology. 2003;61:754-759.
7. Kryvenko ON, Diaz M, Meier FA, et al. Findings in 12-core transrectal ultrasound-guided prostate needle biopsy that predict more advanced cancer at prostatectomy: analysis of 388 biopsy-prostatectomy pairs. Am J Clin Pathol. 2012;137:739-746.
8. Cagiannos I, Karakiewicz P, Eastham JA, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003;170:1798-1803.
9. Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993;150:110-114.
10. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ. 2007;335:1134.
11. Kava BR, Eldefrawy A, Ayyathurai R, et al. Impact of body mass index and tumor location on the incidence of benign histology at the time of nephron-sparing surgery. Int Urol Nephrol. 2012;44:1319-1324.
12. Pierorazio PM, Walsh PC, Partin AW, et al. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013;111:753-760.
13. Kane CJ, Bassett WW, Sadetsky N, et al. Obesity and prostate cancer clinical risk factors at presentation: data from CaPSURE. J Urol. 2005;173:732-736.
14. Epstein JI, Allsbrook WC Jr, Amin MB, et al. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29:1228-1242.
15. Srigley JR. Key issues in handling and reporting radical prostatectomy specimens. Arch Pathol Lab Med. 2006;130:303-317.
16. World Health Organization. Global database on body mass index. http://apps.who.int/bmi/index.jsp?introPage=intro-3.html. Accessed May 25, 2015.
17. Bryniarski P, Paradysz A, Fryczkowski M. PSA mass as a marker of prostate cancer progression after radical prostatectomy. Med Sci Monitor. 2011;17:CR104-CR109.
18. Epstein JI, Walsh PC, Carmichael M, et al. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368-374.
19. Sundi D, Kryvenko ON, Carter HB, et al. Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men. J Urol. 2014;191:60-67.
20. Kryvenko ON, Carter HB, Trock BJ, et al. Biopsy criteria for determining appropriateness for active surveillance in the modern era. Urology. 2014;83:869-874.
21. Capitanio U, Suardi N, Briganti A, et al. Influence of obesity on tumour volume in patients with prostate cancer. BJU Int. 2012;109:678-684.
22. Menon M, Shrivastava A, Kaul S, et al. Vattikuti Institute prostatectomy: contemporary technique and analysis of results. Eur Urol. 2007;51:648-657.
23. Menon M, Tewari A, Peabody J. Vattikuti Institute prostatectomy: technique. J Urol. 2003;169:2289-2292.
24. Duffield AS, Epstein JI. Detection of cancer in radical prostatectomy specimens with no residual carcinoma in the initial review of slides. Am J Surg Pathol. 2009;33:120-125.
25. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology. 2001;58:843-848.
26. Beebe-Dimmer JL, Faerber GJ, Morgenstern H, et al. Body composition and serum prostate-specific antigen: review and findings from Flint Men's Health Study. Urology. 2008;71:554-560.
27. Price MM, Hamilton RJ, Robertson CN, et al. Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. Urology. 2008;71:787-791.
28. Fowke JH, Signorello LB, Chang SS, et al. Effects of obesity and height on prostate-specific antigen (PSA) and percentage of free PSA levels among African-American and Caucasian men. Cancer. 2006;107:2361-2367.
29. Freedland SJ, Sun L, Kane CJ, et al. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. BJU Int. 2008;102:969-974.
30. Danneman D, Drevin L, Robinson D, et al. Gleason inflation 1998-2011: a registry study of 97 168 men. BJU Int. 2015;115:248-255.
31. Amling CL, Riffenburgh RH, Sun L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22:439-445.
32. Partin AW, Epstein JI, Cho KR, et al. Morphometric measurement of tumor volume and per cent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. J Urol. 1989;141:341-345.
33. Parker AS, Thiel DD, Bergstralh E, et al. Obese men have more advanced and more aggressive prostate cancer at time of surgery than non-obese men after adjusting for screening PSA level and age: results from two independent nested case-control studies. Prostate Cancer Prostatic Dis. 2013;16:352-356.
34. Banez LL, Hamilton RJ, Partin AW, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA. 2007;298:2275-2280.
35. Grubb RL III, Black A, Izmirlian G, et al. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev. 2009;18:748-751.
36. Sivanandam A, Siva S, Bhandari M, et al. Variance inflation in sequential calculations of body surface area, plasma volume, and prostate-specific antigen mass. BJU Int. 2008;102:1573-1580.
37. Swanson GP, Epstein JI, Ha CH, et al. Pathologic characteristics of low risk prostate cancer based on totally embedded prostatectomy specimens. Prostate. 2015;75:424-429.